Sage Therapeutics Inc. (SAGE) has faced a challenging year to date, with its share price plummeting 77% from its 52-week high of $22.86 in January, to trade around $6.
This biopharmaceutical company has two FDA-approved treatments indicated for postpartum depression and a robust pipeline to target unmet needs in brain health.
The two marketed drugs are Zurzuvae, approved in August 2023, developed and commercialized in collaboration with Biogen Inc. (BIIB), and Zulresso, approved in March 2019.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.